New search Hide text from Guidelines
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTSThis group comprises preparations used in the treatment of neoplastic diseases, and immunomodulating agents.
Corticosteroids for systemic use, see H02.
L03 IMMUNOSTIMULANTS
Immunosuppressants, see L04A.
L03A IMMUNOSTIMULANTS
Levamisole, which also affects the immune response, is classified in P02CE.
L03AA Colony stimulating factors
The DDDs for pegfilgrastim (L03AA13) and lipegfilgrastim (L03AA14) are based on the declared amount of filgrastim and on the use of one single dose per cycle of chemotherapy. The DDDs for the other G-CSFs are based on daily dosing for six subsequent days. |
ATC code | Name | DDD | U | Adm.R | Note |
L03AA02 | filgrastim | 0.35 | mg | P | |
L03AA03 | molgramostim | 0.35 | mg | P | |
L03AA09 | sargramostim | 0.45 | mg | P | |
L03AA10 | lenograstim | 0.35 | mg | P | |
L03AA12 | ancestim | 1.4 | mg | P | |
L03AA13 | pegfilgrastim | 0.3 | mg | P | |
L03AA14 | lipegfilgrastim | 0.3 | mg | P | |
L03AA15 | balugrastim | ||||
L03AA16 | empegfilgrastim | ||||
L03AA17 | pegteograstim | 0.3 | mg | P | |
L03AA18 | efbemalenograstim alfa | ||||
L03AA19 | eflapegrastim |
Last updated: 2024-01-26